Twist Bioscience (TWST) Forward P/S Multiple
The forward P/S metric demonstrates the market perception of Twist Bioscience (TWST), whose leadership in silicon-based DNA synthesis is confirmed by the value of 17.40. Stability is ensured by diversification into the agricultural sector and data storage, while the growth strategy relies on partnerships with Big Pharma for antibody development without pursuing mergers.
Twist Bioscience Corp - analytical breakdowns and key metrics (TWST)
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- debt level and financial liquidity data:
Debt to Equity Twist Bioscience|TWST - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Twist Bioscience|TWST - Company Total Debt|Debts to Book Capitalization Twist Bioscience Corp|TWST - Long-Term Debt|Company Current Liabilities Twist Bioscience|Quick Liquidity Indicator twistbioscience.com
- financial results and valuation multiples details:
TWST - Net Income|Expected Profit Twist Bioscience|TWST - Business Payback Period|Projected Price to Earnings Twist Bio|TWST - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Twist Bioscience Corp|TWST - Operating profit before amortization|Earnings per share for the last twelve months Twist Bioscience|TWST - Earnings per share for the last 12 months|Quarterly EPS earnings growth twistbioscience.com|TWST - Earnings growth in current year|Expected earnings per share growth for next year Twist Bioscience
- sales volume and revenue indicators:
Analysis of all company metrics:Twist Bioscience, Inc. TWST
Twist Bioscience (TWST) scales DNA synthesis on its own semiconductor platforms with moderate dependence on raw material suppliers. By analyzing the business's forward P/S, an investor assesses the company's market value relative to expected future sales volume. This ratio identifies whether an asset is overvalued or undervalued by correlating the current share price with projected revenue. Monitoring the indicator's extremes allows institutional players to effectively protect capital from volatility.
Competitor analysis
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Market Cap to Expected Sales Ratio Qiagen NV (QGEN)|Ionis Pharma - Forward P/S Multiple|Repligen Inc. (RGEN) - Forward Price-to-Revenue Multiple|RNA: Forward P/S Multiple|CRSP - Market Cap to Expected Sales Ratio|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|Sarepta Corp - Market Cap to Projected Revenue|Forward P/S Multiple TXG (10x Genomics, Inc.)|NTLA - Forward Price-to-Revenue Multiple|Stoke Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio BioLife Solutions Inc|WVE (Wave Life Sciences Corp) - Forward Price-to-Revenue Multiple|MAZE: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple SION|Forward Price-to-Revenue Multiple primemedicine.com (PRME)|Price-to-Projected Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|Market Cap to Expected Sales Ratio uniQure NV|MeiraGTx PLC - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio RGNX (REGENXBIO Corp)|Solid Biosciences Inc. - Forward P/S Multiple|OCGN (ocugen.com) - Market Cap to Projected Revenue|PacBio (PACB) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue BNTC|DSGN (Design Pharma) - Forward P/S Multiple|Forward P/S Multiple Rocket Corp|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics)|Price to Expected Revenue Ratio LXEO|Korro Bio - Forward Price-to-Revenue Multiple|EDIT - Forward Price-to-Revenue Multiple|Silence Therapeutics Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio ProQR Therapeutics N.V. PRQR|codexis.com (CDXS) - Price-to-Projected Revenue Ratio|SGMO - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple NAUT|MGX (Metagenomi Inc.) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple DTIL (Precision BioSciences, Inc.)|GBIO (generationbio.com) - Forward Price to Sales|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|Exicure Inc. - Price-to-Projected Revenue Ratio|Celsion Corporation - Forward P/S Multiple|Market Cap to Expected Sales Ratio Phio Pharmaceuticals PHIO|mustangbio.com (MBIO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio TransCode Therapeutics, Inc. (RNAZ)|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|adnas.com (APDN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple BLUE|Forward Price-to-Revenue Multiple immunoprecise.com IPA|Forward P/S Multiple OMGA (Omega)|Market Cap to Expected Sales Ratio Singular Genomics Corp (OMIC)|Regulus Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio syros.com|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TCON|UBX (Unity Bio) - Forward P/S Multiple
